Asahi Life Asset Management CO. LTD. Invests $350,000 in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Asahi Life Asset Management CO. LTD. purchased a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,065 shares of the medical research company’s stock, valued at approximately $350,000.

Other large investors have also added to or reduced their stakes in the company. Venturi Wealth Management LLC increased its holdings in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after buying an additional 87 shares during the last quarter. Gladius Capital Management LP purchased a new stake in Bio-Rad Laboratories during the third quarter worth about $32,000. Asset Planning Inc purchased a new stake in Bio-Rad Laboratories during the fourth quarter worth about $33,000. UMB Bank n.a. increased its holdings in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after buying an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. purchased a new stake in Bio-Rad Laboratories during the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Price Performance

BIO opened at $264.60 on Friday. The company has a market capitalization of $7.41 billion, a price-to-earnings ratio of -4.07 and a beta of 0.90. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The firm has a 50-day moving average price of $327.02 and a 200-day moving average price of $332.57. Bio-Rad Laboratories, Inc. has a twelve month low of $262.11 and a twelve month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analysts Set New Price Targets

BIO has been the subject of a number of research analyst reports. Wells Fargo & Company decreased their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.